AU2624299A - Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy - Google Patents

Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy

Info

Publication number
AU2624299A
AU2624299A AU26242/99A AU2624299A AU2624299A AU 2624299 A AU2624299 A AU 2624299A AU 26242/99 A AU26242/99 A AU 26242/99A AU 2624299 A AU2624299 A AU 2624299A AU 2624299 A AU2624299 A AU 2624299A
Authority
AU
Australia
Prior art keywords
pharmacotherapy
necrosis
utilization
order
produce preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26242/99A
Inventor
Heribert Schmitt-Willich
Milos Sovak
Ulrich Speck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2624299A publication Critical patent/AU2624299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • A61K47/546Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
AU26242/99A 1998-02-25 1999-02-22 Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy Abandoned AU2624299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3008598A 1998-02-25 1998-02-25
US09030085 1998-02-25
PCT/EP1999/001048 WO1999043317A1 (en) 1998-02-25 1999-02-22 Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy

Publications (1)

Publication Number Publication Date
AU2624299A true AU2624299A (en) 1999-09-15

Family

ID=21852412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26242/99A Abandoned AU2624299A (en) 1998-02-25 1999-02-22 Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy

Country Status (3)

Country Link
AU (1) AU2624299A (en)
DE (1) DE19824653A1 (en)
WO (1) WO1999043317A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
DE19835082A1 (en) * 1998-07-24 2000-02-03 Schering Ag Paramagnetic 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical compositions containing them, processes for their preparation and their use for necrosis and infarct MR imaging
US6251367B1 (en) 1998-07-24 2001-06-26 Schering Aktiengesellschaft Paramagnetic 3-,8-substituted deuteroporphyrin derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7087214B2 (en) * 2002-02-01 2006-08-08 Zentaris Gmbh Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
FR2867189A1 (en) * 2004-03-08 2005-09-09 Ludovic Bourre New compound comprising protein kinase regulator and photoactivatable molecule, useful for treating protein kinase-related diseases, e.g. tumors and inflammation
GB0723124D0 (en) 2007-11-26 2008-01-02 Univ Leuven Kath Targeted radiotherapy
CN115746007A (en) * 2022-12-02 2023-03-07 无锡市南京大学锡山应用生物技术研究所 Compound capable of activating STING pathway as radiotherapy sensitizer and other applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5222134A (en) * 1990-11-07 1993-06-22 Tau Systems Corporation Secure system for activating personal computer software at remote locations
DE4305523A1 (en) * 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-tetraphenylporphyrin complexes, processes for their preparation and pharmaceutical compositions containing them
WO1995031219A1 (en) * 1994-05-11 1995-11-23 Schering Aktiengesellschaft The use of porphyrin-complex or expanded porphyrin-complex compounds as localization diagnosticum for infarction or necrosis
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque

Also Published As

Publication number Publication date
DE19824653A1 (en) 1999-08-26
WO1999043317A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
AU2168597A (en) Improvements in or relating to encapsulation
AU1407699A (en) Distributed architecture utility
AU1884797A (en) Improvements in or relating to contrast agents
AU4714797A (en) Improvements in or relating to contrast agents
AU2553499A (en) Improvements in and relating to recreational devices
AU2546399A (en) Preparations with controlled release
AU2846699A (en) Improvements in or relating to enclosures
AU4636699A (en) Materials and methods relating to encapsulation
AU2624299A (en) Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy
AU2538500A (en) Organo-phosphorus compounds and their utilization
AU6519899A (en) Improvements in and relating to emitters
AU8228498A (en) Improvements in and relating to durometers
AU3617799A (en) Improvements in or relating to contrast agents
AU1577900A (en) Improvements in or relating to pipes
AU9359098A (en) Improvements in or relating to chairs
AU8736598A (en) Improvements in and relating to compounds and complexes
AU1636597A (en) Improvements in or relating to valves
AUPP368498A0 (en) Improvements in decals
AUPP707398A0 (en) Improvements in or relating to balustrading
AUPO614497A0 (en) Improvements in or relating to supports for structures
AU6188198A (en) Improvements in or relating to supports for structures
AUPP679898A0 (en) Improvements in utility folders
AUPO693597A0 (en) Improvements in decals
AUPN998596A0 (en) Improvements in decals
AUPO642597A0 (en) Improvements in push-chairs

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase